GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | MicrobiomeTrials← Back to trialsNCT07087002
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-08-28Est. Completion: 2027-08
Enrollment target: 18 participants Locations- Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
Other microbiome trials you might be interested in
Brain Tumor
Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at re…
St Louis, United StatesEst. completion Apr 30, 2028
Diffuse Midline GliomaDiffuse Midline High-grade GliomaMedulloblastomaEpendymoma
This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG)…
St Louis, United StatesCompleted Aug 31, 2031